Jcr Pharmaceuticals Co., Ltd. · TSE:4552

Jcr Pharmaceuticals — FY2023 Earnings Presentation

20 slides from Jcr Pharmaceuticals's earnings presentation, May 10, 2024

1. Slide 1: Appendix to the Consolidated Financial Summary FY2023 Second-Half

   Appendix to the Consolidated Financial Summary FY2023 Second-Half May 10th, 2024 JCR Pharmaceuticals Co., Ltd. [Securities code]4552, Prime. TSE Note : This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this tra

2. Slide 2: Contents

   Contents Consolidated Financial Results 2 Breakdown of Net Sales – Consolidated 3 Financial Status - Consolidated 4 Cash Flows - Consolidated 5 Consolidated Financial Results FY2024(forecast) 6 Breakdown of Net Sales – Consolidated FY2024(forecast) 7 ＜Reference＞ Net Sales Trends by Product 8 Composi

3. Slide 3: Consolidated Financial Results

   Consolidated Financial Results （Unit: million yen) FY2022 FY2023 ◆ Operating income 7,531 million yen Consolidated Year-on-year Full-year Progress results results forecast Year-on-year: +2,556 million yen rate Difference Ratio (Revised) Net sales 34,343 42,871 +8,528 ＋24.8% 45,400 94.4% 2023年3月期 FY2

4. Slide 4: Breakdown of Net Sales – Consolidated

   Breakdown of Net Sales – Consolidated （Unit: million yen) FY2022 FY2023 Year-on-year Full year ◆Net sales 42,871 million yen Progress Year-on-year;+8,528 million results results forecast Difference Ratio rate (Revised) yen FY2022 2023年3月期 34,343 GROWJECT® 12,261 17,913 +5,652 +46.1% 19,500 91.9% IZC

5. Slide 5: Financial Status - Consolidated

   Financial Status - Consolidated （Unit: million yen） End-Mar. End-Mar. Change End-Mar. End-Mar. Change 2023 2024 ・Main 2023 2024 ・Main Increase/decrease Increase/decrease Total +9,779 Total (5,626) • Cash and deposits • Income taxes Current +5,477 35,762 30,135 payable +1,623 liabilities Current • Ac

6. Slide 6: Cash Flows - Consolidated

   Cash Flows - Consolidated Operating Activities (Unit: million yen) FY2022 FY2023 Year-on-year 営業活動によるCF Investing Activities 投資活動によるCF Profit before income taxes 5,412 7,244 ＋1,831 Financing Activities Depreciation 1,997 3,197 ＋1,199 財務活動によるCF Decrease (increase) in trade receivables and 3,269 (3,39

7. Slide 7: Consolidated Financial Results FY2024 forecast

   Consolidated Financial Results FY2024 forecast （Unit: million yen） FY2023 FY2024(forecast) Consolidated Year-on-year results forecast Difference Ratio Net sales 42,871 41,300 (1,571) (3.7)% Cost of sales 11,620 10,400 (1,220) (10.5)% Gross profit 31,251 30,900 (351) (1.1)% Selling, general and admin

8. Slide 8: Breakdown of Net Sales – Consolidated FY2024 forecast

   Breakdown of Net Sales – Consolidated FY2024 forecast （Unit: million yen） FY2023 FY2024(forecast) Year-on-year results forecast Difference Ratio GROWJECT® 17,913 18,300 +387 +2.2% IZCARGO®* 5,171 5,700 +529 +10.2% TEMCELL®HS Inj. 3,236 2,800 (436) (13.5)% Treatments for renal anemia 4,652 4,200 (452

9. Slide 9: Net Sales Trends by Product

   （Unit: million yen） Net Sales Trends by Product Recombinant therapeutic enzyme for mucopolysaccharidosis II (MPS II) Recombinant human growth hormone product 17,913 IZCARGO® I.V. infusion 10mg GROWJECT® From April 24, 2023: Co-promotion with Sumitomo Pharma Co., Ltd. 13,256 12,945 12,261 5,171 4,414

10. Slide 10: Composition of Net Sales by Item

    Composition of Net Sales by Item ● GROWJECT® 6% 17,913 million yen ● IZCARGO® 5,171 million yen ● TEMCELL®HS Inj. 17% 3,236 million yen Total net sales 42% ● Epoetin Alfa BS Inj. [JCR] 1,994 million yen 4% 42,871 ● Darbepoetin Alfa BS Inj. [JCR] million yen 2,658 million yen ● Agalsidase Beta BS I.V

11. Slide 11: Trends in Sales Breakdown - Consolidated

    Trends in Sales Breakdown - Consolidated （単位：百万円） 8,046 18,391 0 689 23,898 51 14,834 14,712 16,721 67 12,860 4 404 6,329 0 301 AZD1222 stock solution AZD1222原液 51 1,931 2,131 Other その他(イズカーゴNPS含む) 7,557 7,112 Income from contractual payment 契約金 56 10,744 5,536 590 7,438 1,071 Agalsidase ベータBS アガルシダ

12. Slide 12: Net Sales Trends (Excluding AZD1222 Stock Solution)

    Net Sales Trends (Excluding AZD1222 Stock Solution) 製商品*売上高 Products* sales 契約金 payment Income from contractual （Unit: million yen） * Products: GROWJECT, IZCARGO, treatment for renal anemia, TEMCELL, Agalsidase Beta, others 7,413 10,571 6,546 6,406 2,050 35,457 26,134 25,865 22,731 23,275 FY2019 202

13. Slide 13: Trends in Composition Ratio of Cost/Expense

    Trends in Composition Ratio of Cost/Expense (Unit: million yen) Operating profit Operating profit 営業利益 研究開発費 R&D expenses SG&A 販売費・一般管理費 Cost of sales 売上原価 20.5% 26.0% 25.9% 27.1% 31.9% 10,461 7,812 8,886 11,620 7,901 26.5% 28.7% 13,511 34.0% 29.1% 30.8% 8,643 12,484 11,678 7,638 14.0% 7,175 17.8% 5

14. Slide 14: Correlation between R&D Expenses (before Deducting) and Main R&D Pipeline

    Correlation between R&D Expenses (before Deducting) and Main R&D Pipeline (Unit: million yen) Process development/ 15,062 Non-clinical 12,787 Clinical trial 9,480 7,671 5,856 Filed an application Approved FY2020 FY2021 FY2022 FY2023 FY2024（forecast） JR-141 (Japan) JR-141 (Brazil) Aug. 2022: Approval

15. Slide 15: Net Sales Trends by Product FY2024 Forecast

    （Unit: million yen） Net Sales Trends by Product FY2024 Forecast Recombinant therapeutic enzyme for mucopolysaccharidosis II (MPS II) Recombinant human growth hormone product 18,300 IZCARGO® I.V. infusion 10mg GROWJECT® 17,913 From April 24, 2023: Co-promotion with Sumitomo Pharma Co., Ltd. 12,945 12

16. Slide 16: Net Sales Trends (Excluding AZD1222 Stock Solution) FY2024 Forecast

    Net Sales Trends (Excluding AZD1222 Stock Solution) FY2024 Forecast Products* 製商品*売上高sales Income 契約金from contractual payment （Unit: million yen） * Products: GROWJECT, IZCARGO, treatment for renal anemia, TEMCELL, Agalsidase Beta, others 7,413 8,100 10,571 6,546 6,406 35,457 33,200 26,134 25,865 23,

17. Slide 17: IZCARGO Prescription Status

    IZCARGO® Prescription Status Net sales 100 売上高（百万円） (Unit: million yen) 累積症例数（例） Cumulative cases (cases) 投与症例数（例） Administered cases (cases) 88 90 83 85 77 80 74 71 67 59 60 72 73 60 69 70 62 64 45 60 60 56 57 40 43 17 20 17 224 761 1,059 957 1,070 1,047 1,249 1,047 1,215 1,342 1,413 1,201 0 FY2021

18. Slide 18: GROWJECT Market Trends

    GROWJECT® Market Trends Sales amount of each product （Unit: million yen） GH Sales Trends in Japan（Apr. 2023 - Mar. 2024） GH Market in Japan （Unit: million yen） *On an NHI drug price basis 3,500 7,000 3,000 6,000 国内GH市場 2,500 5,000 JCR Groeject® 製品A 2,000 4,000 製品B 1,500 3,000 製品C 製品D 1,000 2,000 製品E

19. Slide 19: GROWJECT Market Trends

    GROWJECT® Market Trends GH Market Share in Japan 60% 49.8% 50% 45.1% 43.4% ■ GROWJECT® Market Share by buyer 40% Mar. 2024 Sales Change 30% 26.0% 26.6% FY2023 Q4 22.9% vs. FY2022 Q4 *On an NHI drug price basis 20% 22.5% 21.2% 13.0% HP Market 35% +929 million yen 10% 7.1% 6.8% 6.6% GP Market 63% +483

20. Slide 20: Copyright © 2024 JCR Pharmaceuticals Co., Ltd. All rights reserved.

    Copyright © 2024 JCR Pharmaceuticals Co., Ltd. All rights reserved.

JCR Pharmaceuticals — FY2023 Earnings Presentation on 6ix